Editas Medicine Inc (EDIT)
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company is building a proprietary gene-editing platform using CRISPR-based technology and is advancing several programs across different therapeutic areas. Its lead program, EDIT-401, is a one-time treatment being developed to help lower LDL cholesterol by increasing LDL receptor activity in patients with hyperlipidemia. Editas is also working on therapies for sickle cell disease and transfusion-dependent beta thalassemia, along with in vivo gene-editing candidates for other cells and tissues. In addition, the company has a research collaboration with Juno Therapeutics to develop experimental alpha-beta T-cell medicines for solid and liquid tumors and autoimmune disease. Founded in 2013, the company is based in Cambridge, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EDIT
|
$2.85
|
-2.5% Downside
|
Fair
|
$6
|
105.5% Upside
|
Bargain
|
Fair
|
0.0%
|
November 9, 2026
|
4.1x
|
9.2x
|
448.5 M
|
238.5 M
|
3.4%
|
75.2%
|
-8.1
|
163.0%
|
